Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
9.06B
Market cap9.06B
Price-Earnings ratio
96.73
Price-Earnings ratio96.73
Dividend yield
Dividend yield
Average volume
693.70K
Average volume693.70K
High today
$86.39
High today$86.39
Low today
$83.60
Low today$83.60
Open price
$85.27
Open price$85.27
Volume
638.79K
Volume638.79K
52 Week high
$117.33
52 Week high$117.33
52 Week low
$49.00
52 Week low$49.00

Stock Snapshot

With a market cap of 9.06B, Corcept Therapeutics(CORT) trades at $86.11. The stock has a price-to-earnings ratio of 96.73.

On 2025-12-06, Corcept Therapeutics(CORT) stock traded between a low of $83.60 and a high of $86.39. Shares are currently priced at $86.11, which is +3.0% above the low and -0.3% below the high.

The Corcept Therapeutics(CORT)'s current trading volume is 638.79K, compared to an average daily volume of 693.7K.

During the past year, Corcept Therapeutics(CORT) stock moved between $49.00 at its lowest and $117.33 at its peak.

During the past year, Corcept Therapeutics(CORT) stock moved between $49.00 at its lowest and $117.33 at its peak.

CORT News

Simply Wall St 7h
Corcept Therapeutics: Reassessing Valuation After Q3 Earnings Beat, Revenue Miss, and Planned CEO Share Sale

Corcept Therapeutics (CORT) just posted third quarter earnings that topped profit expectations even as revenue missed forecasts, and the update landed alongside...

Corcept Therapeutics: Reassessing Valuation After Q3 Earnings Beat, Revenue Miss, and Planned CEO Share Sale
Simply Wall St 6d
How Investors May Respond To Corcept Therapeutics Raising 2025 Revenue Guidance Amid Pharmacy Constraints

Earlier this week, Corcept Therapeutics revised its 2025 revenue guidance to US$800–US$850 million, reflecting capacity constraints with its former specialty ph...

How Investors May Respond To Corcept Therapeutics Raising 2025 Revenue Guidance Amid Pharmacy Constraints

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.